Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation
Article 2021 en
Authors
SL
So-Ryoung Lee
EC
Eue-Keun Choi
SP
Sang Hyun Park
Abstract
1 min read
The off-label underdosed apixaban group showed higher risks of ischaemic stroke, all-cause death, and composite clinical outcomes than the on-label standard dose apixaban group, but both showed comparable risks of MB. Label adherence to apixaban dosing should be emphasized to achieve the best clinical outcomes for Asian patients with AF.
Discussion(0)
No comments yet. Be the first to comment.